What are the keytruda long term benefits?

What long-term data exists for Keytruda?

Long-term follow-up from the KEYNOTE-006 trial shows patients with advanced melanoma who responded to Keytruda often maintained that response for years. Five-year survival rates reached 34 percent in the every-three-weeks dosing arm and 39 percent in the every-two-weeks dosing arm, compared with 18 percent in the ipilimumab group. Some patients remained progression-free at the fünf-year mark.

How does Keytruda fare in non-small cell lung cancer over time?

In the KEYNOTE-001 study, patients with previously treated advanced NSCLC showed 5-year survival rates of 23 percent when they received Keytruda as monotherapy. Patients who achieved a complete or partial response maintained those responses for a median duration of 16.8 months. Those who received Keytrude in the first-line setting showed 5-year survival rates of 23 percent as well.

What happens if patients stop Keytruda early?

In the KEYNOTE-006 melanoma study, patients who stopped treatment after two years of Keytruda still showed 87 percent progression-free survival two years later. Similar two-year progression-free rates were recorded in the KEYNOTE-010 and KEYNOTE-024 lung-cancer studies after discontinuation at two years.

Are there risks tied to long-term use?

Patients on Keytruda for years may develop immune-related adverse events such as endocrinopathies, pneumonitis, or colitis that can require lifelong hormone replacement or other treatment. Some patients remain on low-dose steroids indefinitely.